BZF 961Alternative Names: BZF961
Latest Information Update: 19 Feb 2016
At a glance
- Originator Novartis
- Class Antivirals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 18 Feb 2016 Discontinued - Phase-I/II for Hepatitis C in USA (unspecified route)
- 31 Mar 2013 Phase-I/II clinical trials in Hepatitis C in USA (unspecified route)